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Using COVID-19 Vaccine Efficacy Data to Teach One-Sample Hypothesis Testing
Abstract
In late November 2020, there was a flurry of media coverage of two companies’ claims of 95% efficacy
rates of newly developed COVID-19 vaccines, but information about the confidence interval was not
reported. This paper presents a way of teaching the concept of hypothesis testing and the construction of
confidence intervals using numbers announced by the drug makers Pfizer and Moderna publicized by the
media. Instead of a two-sample test or more complicated statistical models, we use the elementary oneproportion z-test to analyze the data. The method is designed to be accessible for students who have only
taken a one-semester elementary statistics course. We will justify the use of a z-distribution as an
approximation for the confidence interval of the efficacy rate. Bayes’s rule will be applied to relate the
probability of being in the vaccine group among the volunteers who were infected by COVID-19 to the
more consequential probability of being infected by COVID-19 given that the person is vaccinated.
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Introduction
On November 21, 2020, the New York Times featured the article “What Does It
Mean if 2 Companies Report 95% Efficacy Rates?” Carl Zimmer wrote, “In the
case of Pfizer, for example, the company recruited 43,661 volunteers and waited
for 170 people to come down with symptoms of COVID-19 and then get a positive
test. Out of these 170, 162 had received a placebo shot, and just eight had received
the real vaccine” (2020).
On November 30, 2020, the drug maker Moderna issued a press release
containing the following statement:
Today’s primary analysis was based on 196 cases, of which 185 cases of COVID-19 were
observed in the placebo group versus 11 cases observed in the mRNA-1273 group,
resulting in a point estimate of vaccine efficacy of 94.1%. . . . The Phase 3 COVE trial is a
randomized, 1:1 placebo-controlled study testing mRNA-1273 at the 100 µg dose level in
30,000 participants in the U.S., ages 18 and older (Moderna 2020).

The COVID-19 pandemic has produced a deluge of news coverage of
quantitative concepts (Ancker 2020). Madison et al. (2012) have written a textbook
to illustrate the value of using media articles for quantitative reasoning. COVID
vaccine efficacy is arguably the most important statistical news in students’
lifetimes, and information given in the above quotes offers a uniquely powerful
teaching opportunity to demonstrate how numbers are used in shaping public
policy. The objective of this paper is to elucidate the meaning of these numbers in
the context of hypothesis testing and confidence intervals for the efficacy rate.
Without the confidence interval, a crucial piece of information is missing.
Because the vaccine development typically involves an experimental group
and a placebo-controlled group, a two-sample hypothesis testing is a suitable
statistical procedure to analyze data. Such a topic is usually presented in a second
statistics course. For example, at the author’s institution, an urban public university,
MAT 120 Elementary Statistics I covers up to one-sample z- and t-tests, and twosample methods are taught in MAT 121 Elementary Statistics II. Currently, there
are 39 sections of MAT 120, but only 1 section of MAT 121, and our situation is
quite common, meaning that most students do not have the mathematical tools to
analyze news stories concerning vaccine trials. The impetus behind this note is to
provide a path forward for educators of first-semester statistics through reframing
the data in the news as a one-sample hypothesis test.
In the next section we introduce the principle of hypothesis testing by
comparing vaccine trials with coin flipping to make the concept comprehensible
for a lay person. Then we use both the p-value and confidence-interval approaches
to test hypotheses for one parameter presented in standard textbooks. The following
section is concerned with the efficacy rate, its dependence on the number of sick
people who are vaccinated, and its linear approximation. The rest of the sections
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are mathematical justification of our approximation to allow practitioners to verify
our methodology. Further technical details, including a simulation for the
confidence interval, are presented in the Appendix.

Principle of Hypothesis Testing
To transform the two-sample problem into a single-sample problem appropriate for
many introductory courses, assume that half of the 43,661 volunteers in the Pfizer
trial mentioned in the New York Times article received the real vaccine, and the
other half received a placebo shot. (The Moderna press release explicitly states a
1:1 ratio in their trial.) Out of the 170 people who later became COVID-positive, if
the vaccine is ineffective, which is always the null hypothesis in a medical
experiment (Ancker and Begg 2017), we expect 0.5×170 = 85 people to be in the
placebo group and 85 people in the vaccine group. But common sense informs us
that the actual outcome may not be 85 exactly. It is analogous to tossing a fair coin
170 times and counting the number of heads. One should not be surprised to see 86
or 83 heads.
Figure 1 shows the theoretical probability of getting x heads after tossing a fair
coin 170 times, and it is the same probability of observing x volunteers in the
placebo group among the 170 people who were infected by the coronavirus, under
the null hypothesis that the vaccine is doing nothing. The figure is produced using
the open-source software R, and the command is shown in the figure caption so that
educators can change the numbers to produce a new plot for a different situation.
We see that the probability attains a maximum when x = 85 and decreases as x
deviates from 85.

Figure 1. The figure is produced using R with the command plot(dbinom(0:170, 170, 0.5)).
For the Moderna trial, we replace 170 with 196.
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Let us imagine an outcome that among the 170 people who were COVID
positive, 80 were in the vaccine group, and 90 in the placebo group. Although it
appears that the infection rate is smaller for the vaccine group, we cannot be sure
whether this outcome occurs by chance or is due to the vaccine. Examining Figure
1, there is a noticeable probability for x = 90, so it could be by luck that more people
in the placebo group and fewer people in the vaccine group got infected. However,
Pfizer’s actual data show x = 162, and from Figure 1 we see that the probability is
visually indistinguishable from zero for x > 105 or x < 65. It will be unreasonable
to claim that Pfizer’s number, x = 162, happens by chance, and this leads scientists
to conclude that the vaccine is making a difference. Such a probabilistic
consideration is the essence of hypothesis testing.
According to a New York Times report (LaFraniere et al. 2020), on November
8, 2020, Pfizer’s chief executive, Dr. Albert Bourla, was told that 90 out of 94
people who had gotten sick were in the placebo group. The CEO demanded the
scientist to “repeat it, did you say 19 or 90?” It appeared that the CEO was
astonished by the unexpected high efficacy. Statisticians use a number called the pvalue to measure how surprising the data are, given the null hypothesis. We will
find the p-value shortly.
Students might want to know how the probabilities in Figure 1 are obtained.
Returning to the coin-tossing example, if we toss a coin twice, there is one way of
getting two tails, two ways of getting one heads and one tails, and one way of
getting two heads, so the probability of getting 0, 1, and 2 heads is proportional to
1:2:1. Applying the same consideration, if we toss a coin three times, the probability
of getting 0, 1, 2, and 3 heads is proportional to 1:3:3:1. Mathematicians recognized
a pattern, and proved that the probability for x heads in n coin tosses is proportional
to the nth line of Pascal’s triangle. It goes without saying that writing 170 lines of
Pascal’s triangle will be at least tedious if at all practical, and the need to enumerate
efficiently is the driving force for developing mathematical theorems to simplify
the calculation for a large number.
While statisticians reject the null hypothesis that Pfizer’s result occurs purely
by chance, there are still unanswered questions. We need to recognize that no
vaccine offers 100% protection. It is possible that a person in the vaccine group
gets infected with COVID-19, and it is also possible that a person in the placebo
group avoids the virus. We need to quantify such occurrences when developing
public policy. The estimation of the vaccine efficacy rate requires further statistical
techniques, which will be discussed in the subsequent sections.
Although some students find the topic of hypothesis testing alien, we have
shown that the underlying idea is just counting and evaluating plausibility. We
remark that psychologists have found evidence that it is easier for the human mind
to consider the count instead of percentage (Gigerenzer and Hoffrage 1995;
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Cosmides and Tooby 1996). For example, instead of saying 8%, when the same
information is presented as 8 out of 100 people, research subjects vastly improved
their estimation of probability. The author has replicated some psychological
studies with community college students and reached a similar conclusion (Wang
2015). Our demonstration of hypothesis testing using the count instead of
percentage is guided by psychological principles.

One-Proportion z-Test
Textbooks usually present two ways of answering the question about the null
hypothesis: confidence intervals and hypothesis tests. They look at the same
problem from two perspectives. The confidence interval is data-centric, and a
hypothesis test is model-centric (De Veaux et al. 2020). We use both approaches to
analyze the Pfizer data.
We have seen that the probability of getting x heads after tossing a fair coin n
times is proportional to the nth line of Pascal’s triangle. More formally, the
probability follows a binomial distribution, and the probability of observing x heads
is written as
𝑃(𝑥) = 𝐶𝑥𝑛 𝑝 𝑥 (1 − 𝑝)𝑛−𝑥
where p = 1/2 for a fair coin but can be other values between 0 and 1, and
𝐶𝑥𝑛 =

𝑛!
𝑥! (𝑛 − 𝑥)!

is the binomial coefficient. The algorithm of Pascal’s triangle reflects the
𝑛−1
recurrence relation 𝐶𝑥𝑛 = 𝐶𝑥𝑛−1 + 𝐶𝑥−1
.
Abraham de Moivre (1667–1754), a mathematician and consultant to
gamblers, noted that the shape of the binomial distribution approaches a very
smooth curve if n is large. Students might have already noted this in Figure 1. The
bell-shaped curve is the probability density function of a normal distribution. For
a normal distribution with mean 0 and standard deviation 1, it is called the zdistribution. While many students are intimidated by the formulas, we emphasize
that the z-distribution is rooted in elementary counting. If students understand the
principle, they can use computer programs such as R to implement calculations.
Instead of counting the number of heads, in statistics literature the proportion
is used. (The change from counts to proportions is perhaps one reason that students
find statistics hard, based on the psychological studies mentioned earlier.) Let the
true probability of getting heads when flipping a coin be p, the sampling distribution
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for the proportion of heads after n tosses is a normal distribution with mean p and
standard deviation
𝑝(1 − 𝑝)
𝜎𝑝̂ = √
.
𝑛
We point out that the inverse square-root dependence of the standard deviation
on n is the most important result in statistics. Howard Wainer’s 2007 essay “The
Most Dangerous Equation” refers to this equation’s critical importance, and he cites
past havoc because of ignorance of how sample size affects statistical variation.
This equation explains the need for drug makers to wait for a certain number of
volunteers to be COVID-positive before their result becomes statistically
significant. Rebecca Robbins (2020) reported in the New York Times that the surge
in coronavirus cases worldwide is actually helping researchers measure more
quickly how well their vaccines protect against COVID-19. Specifically,
In late-stage vaccine trials, the faster that participants get sick, the faster that drug
developers gain enough data to know whether their vaccines are effective. . . . The trial
ends after a certain number of cases—around 150 to 170—have accrued. That number is
chosen to make sure the results have sufficient statistical power to tell how well the vaccine
works.

For a hypothesized ineffective vaccine, the proportion of volunteers who
received a placebo shot among sick people is p = 1/2, based on the assumption that
the number of people in the vaccine and placebo groups is the same, just like
flipping a fair coin. In the Pfizer trial, n = 170 and 𝜎𝑝̂ = √0.5 (0.5)/170 = 0.038.
We expect the distribution of sample proportions to be the bell-shaped curve in
Figure 2.
The observed sample proportion in the Pfizer trial is
𝑝̂ =

162
= 0.953.
170

It is apparent that the observed sample proportion is very far from the null
hypothesis p = 0.5. The test statistic measures the deviation in terms of standard
deviation,
𝑧=
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Figure 2. We use a normal distribution to approximate the binomial distribution in Figure 1, and
the horizontal axis here is the proportion x/n = x/170. The vertical line indicates the observed
sample proportion measured in the Pfizer vaccine trial.

The probability for an observation to have z ≥ 11.81, or the area under the bellshaped curve to the right of the vertical line, is 1.73 × 10−32 (using R’s pnorm(11.81)). This is the p-value, and in this case it means the probability of observing 𝑝̂
≥ 0.953, if the null hypothesis is true. Because the p-value is essentially zero, we
reject the null hypothesis that the vaccine is ineffective. Comparing Figures 1 and
2, it should be clear that this formal approach also reaches the same conclusion.
The main difference is that we use a normal distribution as an approximation of
probability, and we use the proportion x/n as the variable instead of the count x.
There have been prevalent misconceptions about statistical significance, and
all students should be encouraged to read the statement on p-values by the
American Statistical Association (Wasserstein and Lazar 2016). Principle 3 says
“scientific conclusions and business or policy decisions should not be based only
on whether a p-value passes a specific threshold.”
We introduce the confidence-interval approach to go beyond the p-value. To
estimate the confidence interval for the proportion of people in the placebo group
among the 170 COVID-positive cases, we use
𝑝̂ (1 − 𝑝̂ )
𝑝̂ ± 𝑧𝛼/2 √
𝑛
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where zα/2 is the critical value. For the most commonly used 95% confidence level,
zα/2 = 1.96. One should pay attention to the use of the estimated sample proportion
𝑝̂ for the standard error, instead of the hypothesized population parameter p. The
numbers provided by Pfizer give

[0.953 ± 1.96 √

0.953 (1 − 0.953)
] = [0.921,0.985].
170

Because p = 0.5 is outside the 95% confidence interval, we reject the null
hypothesis, the same conclusion as before. In canned language, students are
typically instructed by textbooks to say, “I am 95% confident that the true
proportion of people who did not get the vaccine, among people who are COVIDpositive, is between 92.1% and 98.5%.” While the statement captures some aspects
of the idea, we remind the readers that the interpretation of confidence intervals is
subtle. Further insight on this important topic is provided by Gelman and Nolan
(2011).
In the next section we will show that Pfizer’s confidence interval, 92.1% to
98.5%, serves as an approximation for the vaccine efficacy rate. In the Moderna
trial, the efficacy rate is approximated by 185/196 = 94.4% based on the company’s
press release, and the 95% confidence interval is estimated to be
0.944 (1 − 0.944)
[0.944 ± 1.96 √
] = [0.926, 0.962].
196
The confidence interval provides much more information than a single number,
and the above calculations serve as an example that we can extract such crucial
information from news articles if we scrutinize the press releases.

Vaccine Efficacy Rate and Its Linear Approximation
While news reports of “statistical significance” can be discussed without the
addition of new terminology, the concept of vaccine “efficacy” lies outside
traditional introductions to statistics. But with a little additional work, this too is
fertile ground for instruction. The definition of efficacy can be found in Zimmer’s
New York Times article:
From these numbers, Pfizer’s researchers calculated the fraction of volunteers in each
group who got sick. Both fractions were small, but the fraction of unvaccinated volunteers
who got sick was much bigger than the fraction of vaccinated ones. The scientists then
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determined the relative difference between those two fractions. Scientists express that
difference with a value they call efficacy. If there’s no difference between the vaccine and
placebo groups, the efficacy is zero. If none of the sick people had been vaccinated, the
efficacy is 100 percent (2020).

Let the number of volunteers 43,661 be N, and let the number of COVID-19
cases in the control group among the 170 sick people be x. Pfizer reported x = 162,
but we keep x as a variable. The sample proportion for people who got sick in the
vaccine group is
𝑝̂𝑣 =

170 − 𝑥
,
𝑁/2

and that in the control group is
𝑝̂𝑐 =

𝑥
.
𝑁/2

The efficacy rate is
𝑒=−

𝑝̂𝑣 − 𝑝̂𝑐
170 − 𝑥
=1−
.
𝑝̂𝑐
𝑥

We plot the efficacy rate as a function of x in Figure 3. As stated in the above
quote, if there is no difference between the vaccine and placebo group, or x = 170/2
= 85, the efficacy is zero. If none of the sick people had been vaccinated, or x =
170, the efficacy is 100 percent. For Pfizer’s trial, x = 162, and e = 1−8/162 = 0.951,
which is the basis of the company’s claim of 95% efficacy rate. For Moderna, the
efficacy rate is 1 − 11/185 = 94.1% from the numbers given in the press release.
To help the general public understand the meaning of Pfizer’s 95% efficacy
rate, let us imagine two otherwise identical communities, but one is vaccinated and
the other is not. For every 100 people who become COVID-positive in the
unvaccinated community, there will only be 5 infections in the vaccinated
community. Consider an inferior vaccine, say with an efficacy rate of 75%, the
number of cases in a vaccinated community will be 25, compared with 100 in an
unvaccinated community. Because any medical system has a limited capacity, the
efficacy rate clearly plays a crucial role in public health planning.
Although it is a calculus topic, it is not difficult to understand that one can
approximate a curve by a straight line within a small interval (see the dashed line
in Figure 3). If x is near 170, we can put 170 in the denominator of e and obtain a
linear approximation:
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𝑒 ≈1−

170 − 𝑥
𝑥
=
.
170
170

This linear relation between e and x is the reason that we could use the z-distribution
to construct the confidence interval for the efficacy rate (when it is greater than
90%) in the preceding section.

Figure 3. The curve is the efficacy rate as a function of number of x volunteers in the
control group who got infected among the 170 people who got infected. The dashed line
is a linear approximation of the function near x = 170.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious
Diseases, said before trial results were published that he would be satisfied with a
75% effective vaccine (Grady 2020). At such a rate, we can solve the equation
1−

170 − 𝑥
= 0.75
𝑥

to find x = 136. The Food and Drug Administration even said it would consider
granting emergency approval for vaccines that showed just 50 percent efficacy
(Zimmer 2020), and in this case 𝑥 ≈ 113. (Instructors can ask students to find x
for other efficacy rates.) As seen in Figure 3, the discrepancy between e and its
linear approximation is noticeable when x is less than about 150. In the Appendix
we will show how to obtain the confidence interval for any x value using a
simulation method.
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Two-Proportion z-Test
As mentioned in the Introduction, it is natural to perform a hypothesis test for twosample proportions for a medical experiment. For courses that teach a two-sample
test, the vaccine trials offer relevant applications. Referring to the notation in the
preceding section, we want to determine whether the infection rates for the placebo
group and the vaccine group are different, in other words, whether pc − pv differs
from zero. The test statistic is
𝑝̂𝑐 − 𝑝̂𝑣

𝑧=

,

1
1
√𝑝̂ (1 − 𝑝̂ ) ( 𝑁 + 𝑁 )
2
2
where 𝑝̂ = 170/𝑁 in Pfizer’s trial. Simplifying it, we have
𝑧=

2𝑥 − 170

√𝑁

√170

√𝑁 − 170

≈

2𝑥 − 170
√170

The approximation is based on the fact that lim

for 𝑁 ≫ 170.

√𝑁

𝑁→∞ √𝑁−170

43,661, and the factor

√43661
√43661−170

= 1. In Pfizer’s trial, N =

= 1.002 plays a minor role in calculating z. As N

tends to infinity, it gets canceled out. As stated previously, the sample size is the
most important consideration in inferential statistics. We see that the number of
volunteers N = 43,661 is less important, but the number of sick people (170) plays
the role of the sample size because of z’s inverse square-root dependence on it.
2×162−170
With x = 162, 𝑧 =
1.02 = 11.83 for the two-sample test, not too
√170

different from the one-sample z-test, 11.81. If we drop the factor of 1.02, the test
statistics for the one-sample and two-sample tests are exactly the same. We will use
R to double check these numbers in the Appendix.

Bayes’s Rule
Finally, publicly reported data from vaccine trials can reinforce lessons from
Bayes’s Rule. The ratio x/170 we have been using estimates the probability that a
person is in the placebo group, given that the person is COVID-positive. In
conditional probability notation, we write it as P(placebo|COVID+). Similarly,
(170 − x)/170 is the probability that a person is in the vaccine group, given that the
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person is COVID-positive denoted by P(vaccine|COVID+). However, the more
relevant conditional probability is the inverse: P(COVID+|vaccine), the probability
of getting infected by coronavirus, given that the person is vaccinated. The
confusion between conditional probability and its inverse is part of Daniel
Kahneman’s Nobel Prize-winning research summarized in his popular book
Thinking, Fast and Slow (Kahneman 2011). Lewis (2021) discusses probabilities
in the context of the pandemic in this Journal.
As seen in previous sections, we have been using numbers from newspapers,
so what we had was P(vaccine|COVID+). To obtain the inverse probability, we
need Bayes’s rule. The simplest form of Bayes’s rule is in odds form, posterior
odds = prior odds × likelihood ratio (Kahneman 2011; Gelman et al. 2013).
Textbooks usually present Bayes’s rule in probabilistic form, and in the present
case
𝑃(vaccine|COVID+) =

𝑃(COVID+|vaccine) 𝑃(vaccine)
𝑃(COVID+)

and
𝑃(placebo|COVID+) =

𝑃(COVID+|placebo) 𝑃(placebo)
.
𝑃(COVID+)

The odds form is the ratio of these two probabilities,
𝑃(vaccine|COVID+) 𝑃(vaccine) 𝑃(COVID+|vaccine)
=
×
.
𝑃(placebo|COVID+) 𝑃(placebo) 𝑃(COVID+|placebo)
The description “posterior odds = prior odds × likelihood ratio” mentioned earlier
is more explicit now.
Kahneman and other psychologists found that people tend to neglect the prior
odds, and such an oversight leads them to confuse between conditional probability
and its inverse. However, for a 1:1 placebo-controlled study,
𝑃(vaccine) = 𝑃(placebo)
and the prior odds can be neglected. We obtain
𝑃(vaccine|COVID+) 𝑃(COVID+|vaccine)
=
.
𝑃(placebo|COVID+) 𝑃(COVID+|placebo)
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Our inference of the probability of getting coronavirus among people who receive
the vaccine, based on the inverse conditional probability from the newspaper
articles, is justified.

Conclusion
COVID-19 presents a major challenge to citizenship, and it is important that people
understand the meaning of numbers so that they can use that knowledge to guide
their behavior (Best 2020). We have demonstrated that much information can be
obtained from numbers related to vaccine trials reported in the media with great
effect in courses that teach introductory statistics. With the fortuitous high vaccine
efficacy rate, we have simplified the hypothesis testing so that students with basic
statistical training can understand the results and undertake the analysis by
themselves. In an era of misinformation and disinformation, numeracy skills
empower citizens and help them make better personal and public decisions.
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Appendix
Most practitioners use software to perform statistical analysis. Below is the R
command and output for a two-sample proportion test based on Carl Zimmer’s
article (2020).
prop.test(c(162, 8), c(43661/2, 43661/2))
2-sample test for equality of proportions
data: c(162, 8) out of c(43661/2, 43661/2)
X-squared = 138.24, df = 1, p-value < 2.2e-16
alternative hypothesis: two.sided
95 percent confidence interval:
0.005842099 0.008266602
sample estimates:
prop 1
prop 2
0.0074208103 0.0003664598

To conduct a one-sample proportion test, we have the following. The
continuity correction is turned off so that we can compare χ2 with z2.
prop.test(162, 170, correct = FALSE)
1-sample proportions test without continuity correction
data: 162 out of 170, null probability 0.5
X-squared = 139.51, df = 1, p-value < 2.2e-16
alternative hypothesis: true p is not equal to 0.5
95 percent confidence interval:
0.9099002 0.9759645
sample estimates:
p
0.9529412

The χ2 values for the two-sample and one-sample tests are 138.24 and 139.51,
respectively, and they are not too different from each other. The χ2 value for the
one-sample test should be the square of the test statistic, and indeed the test statistic
in the main text is the same as the software’s output: 11.812 = 139.51. We confirm
that our one-sample approximation is satisfactory.
Without relying on the linear approximation, we generate 1,000,000 random
numbers from a binomial distribution with size 170 and probabilities 8/170 and
162/170, and calculate 1,000,000 efficacy rates; see the R output shown Figure A.1.
The 95% confidence interval for the Pfizer trial based on our simulation is [0.914,
0.981]. The z-distribution confidence interval [0.921, 0.985] in the main text is up
to the mark with the simulation. The discrepancy can be explained by the use of the
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normal distribution to approximate the binomial distribution, and the linear
approximation of the efficacy rate discussed in the section on efficacy. We conclude
that for a high efficacy rate (> 90%), the method of using the one-proportion z-test
gives a reasonable estimate. If the efficacy is less than 90%, we need to use other
methods such as the simulation introduced here to obtain the confidence interval.

Figure A.1. The histogram of simulated 1,000,000 vaccine efficacy rates produced by R.

set.seed(2)
y <- rbinom(1e6, 170, 8/170)
x <- rbinom(1e6, 170, 162/170)
e <- 1 - y/x
hist(e, probability = TRUE)
quantile(e, c(.025, .975))
2.5%
97.5%
0.9141104 0.9814815
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